Namzaric

The FDA on Wednesday approved a New Drug Application for Adamas Pharmaceuticals Inc's (NASDAQ: ADMS) Namzaric for the treatment of moderate to severe dementia of the Alzheimer's type. Namzaric will be available in two dosage strengths, 28/10 mg and 14/10 mg for patients with severe...